<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26688">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01838915</url>
  </required_header>
  <id_info>
    <org_study_id>11/284</org_study_id>
    <nct_id>NCT01838915</nct_id>
  </id_info>
  <brief_title>Randomized Placebo-controlled Pilot Trial of Prebiotics+Glutamine in HIV Infection</brief_title>
  <acronym>MicroVIH</acronym>
  <official_title>Gut Microbiota, Bacterial Translocation, Immune Activation and Endothelial Dysfunction in HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal</source>
  <oversight_info>
    <authority>Spain: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A rapid and almost complete loss of CD4+ T cells from the gut associated lymphoid tissue
      (GALT) occurs early in HIV infection, with a permanent damage in the intestinal barrier,
      changes in gut microbiota, increased bacterial translocation and persistent immune
      activation, changes that are not restored after the initiation of antiretroviral therapy.
      The investigators hypothesize than an intervention targetting the enterocyte barrier and the
      gut microbiota might modify the gastrointestinal tract towards a bifidogenic microbiota and
      improve markers of  bacterial translocation, inflammation, immune activation and endothelial
      dysfunction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized placebo-controlled clinical trial to evaluate the safety and
      effectiveness to modify gut microbiota, bacterial translocation, immune activation and
      markers of endothelial dysfunction of a dietary supplement (prebiotics + glutamine) during a
      period of six weeks. The study will enroll four cohorts: 1) HIV-infected, treatment naive
      individuals; 2) HIV-infected subjects, currently on ART, with  &gt;350 CD4+ T-cells/uL; 3)
      HIV-infected subjects, currently on ART, with &lt;350 CD4+ T-cells/uL; 4) HIV negative healthy
      controls.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events monitoring during the intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in markers of bacterial translocation</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Soluble CD14 and increasing permeability binding protein.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in markers of immunoactivation</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes in percentages of CD4+ and CD8+ T-cells expressing CD25, HLADR, CD38.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in inflammatory markers</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes in interleukine-6 and high-sensitivity C Reactive Protein</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in markers of endothelial dysfunction</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes in asymmetric dimethylarginine and flow-mediated dilation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in gut microbiota composition</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Changes in gut microbiota as determined by 454 pyrosequencing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in gut microbiota</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes in gut microbiota by 454 pyrosequencing of fecal samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease progression in HIV-infected patients.</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Levels of CD4+ T-cell and HIV-1 RNA copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thymic function</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene expression in peripheral blood monocytic cells.</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Dietary  Supplement: Prebiotics+Glutamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Prebiotics+Glutamine</intervention_name>
    <description>Prebiotics are nondigestible food ingredients, generally oligosaccharides, that modify intestinal microbiota balance by stimulating the growth of beneficial bacteria.
Glutamine is a non-essential amino acid that can be metabolized by epithelial cells, enhancing barrier function.</description>
    <arm_group_label>Dietary  Supplement: Prebiotics+Glutamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Maltodextrin, 20 g.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  After receiving information on the design and objectives of the study, the possible
             risks involved, and the fact that they can refuse to collaborate at any time,
             patients will give their informed consent to participate in the study and agree to
             provide material for the cellular and molecular studies.

          -  Aged over 18 years.

          -  Group 1: HIV+, Not receiving ART and no previous exposure to ART, at least 2 years
             since HIV diagnosis.

          -  Group 2: HIV+, currently receiving ART for more than 2 years, HIV-1 RNA levels less
             than 40 copies/ml and more than 350 CD4+ T-cells/uL.

          -  Group 3: HIV+, currently receiving ART for more than 2 years, HIV-1 RNA levels less
             than 40 copies/ml and less than 350 CD4+ T-cells/uL.

          -  Group 4: HIV-, healthy controls.

        Exclusion Criteria:

          -  Major cardiovascular risk factors.

          -  Concomitant acute diseases.

          -  Gastrointestinal disorders.

          -  Pregnancy.

          -  Antibiotic exposure in the previous month.

          -  Regular use of foods or supplements containing prebiotics or probiotics within the 2
             weeks prior to initiation of the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal and Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 2, 2013</lastchanged_date>
  <firstreceived_date>April 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal</investigator_affiliation>
    <investigator_full_name>Sergio Serrano-Villar</investigator_full_name>
    <investigator_title>Post-Doctoral Researcher</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>immunoactivation</keyword>
  <keyword>bacterial translocation</keyword>
  <keyword>prebiotics</keyword>
  <keyword>glutamine</keyword>
  <keyword>microbiota</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
